Uptake and metabolism of plasma-derived erucic acid by rat brain
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
We examined the ability of erucic acid (22:1n-9) to cross the blood-brain barrier (BBB) by infusing [14-14C]22:1n-9 (170 microCi/kg, iv and icv) into awake, male rats. [1-14C]arachidonic acid (20:4n-6) [intravenous (i.v.)] was the positive control. After i.v. infusion, 0.011% of the plasma [14-14C]22:1n-9 was extracted by the brain, compared with 0.055% of the plasma [1-14C]20:4n-6. The [14-14C]22:1n-9 was extensively beta-oxidized (60%), compared with 30% for [1-14C]20:4n-6. Although 20:4n-6 was targeted primarily to phospholipid pools, 22:1n-9 was targeted to cholesteryl esters, triglycerides, and phospholipids. When [14-14C]22:1n-9 was infused directly into the fourth ventricle of the brain [intracerebroventricular (i.c.v.)] for 7 days, 60% of the tracer entered the phospholipid pools, similar to the distribution observed for [1-14C]20:4n-6. This demonstrates plasticity in the ability of the brain to esterify 22:1n-9 in an exposure-dependent manner. In i.v. and i.c.v. infused rats, a significant amount of tracer found in the phospholipid pools underwent sequential rounds of chain shortening and was found as [12-14C]20:1n-9 and [10-14C]oleic acid. These results demonstrate for the first time that intact 22:1n-9 crosses the BBB, is incorporated into specific lipid pools, and is chain-shortened.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters
Mosser, J., Douar, A.-M., Sarde, C.-O., Kioschis, P., Feil, R., Moser, H., Poustka, A.-M., Mandel, J.-L., & Aubourg, P. (1993) · Nature · doi:10.1038/361726a0 · Cited by 1,202
Qualitative alteration in substrate specificity of mitochondrial monoamine oxidase in brain
Moskvitina, T. A., Kamyshanskaya, N. S., Kaverina, L. P., & Gorkin, V. Z. (1976) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1976.tb04462.x · Cited by 440
Moser, H. (1981) · doi:10.1212/wnl.31.10.1241 · Cited by 396 · cited 2×
“hexacosanoic acid (26:0), in plasma (2, 3), adrenal tissue, and brain (3, 4).”
BackgroundMethodA mouse model for X-linked adrenoleukodystrophy
Lu, J.-F., Lawler, A. M., Watkins, P. A., Powers, J. M., Moser, A. B., Moser, H. W., & Smith, K. D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.17.9366 · Cited by 293 · cited 2×
“X-ALD on this elongation was not determined using mouse models (28, 29).”
MethodResultGene redundancy and pharmacological gene therapy: Implications for X-linked adrenoleukodystrophy
Kemp, S., Wei, H.-M., Lu, J.-F., Braiterman, L. T., McGuinness, M. C., Moser, A. B., Watkins, P. A., & Smith, K. D. (1998) · Nature Medicine · doi:10.1038/3242 · Cited by 249
Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil
Moser, H. W., Raymond, G. V., Lu, S.-E., Muenz, L. R., Moser, A. B., Xu, J., Jones, R. O., Loes, D. J., Melhem, E. R., Dubey, P., et al. (2005) · Archives of Neurology · doi:10.1001/archneur.62.7.1073 · Cited by 239 · cited 2×
“the use of LO in patients is effective (42, 43), but only in patients without neurological involvement (64).”
BackgroundMethodPujol, A. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.499 · Cited by 214 · cited 1×
“Rather, the aged, gene-ablated mice demonstrate signs of adrenomyeloneuropathy (31), a much milder adult form of the disease associated with progressive demyelination in the spinal cord.”
BackgroundDietary erucic acid therapy for X‐linked adrenoleukodystrophy
Rizzo, W. B., Leshner, R. T., Odone, A., Dammann, A. L., Craft, D. A., Jensen, M. E., Jennings, S. S., Davis, S., Jaitly, R., & Sgro, J. A. (1989) · Neurology · doi:10.1212/wnl.39.11.1415 · Cited by 207
Ho, J. K., Moser, H., Kishimoto, Y., & Hamilton, J. A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118182 · Cited by 199 · cited 1×
“brane (7) may account for the demyelination observed in X-ALD.”
BackgroundKobayashi, T., Shinnoh, N., Kondo, A., & Yamada, T. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6340 · Cited by 197 · cited 2×
“X-ALD on this elongation was not determined using mouse models (28, 29).”
MethodResult
Cited by
Barceló-Coblijn, G., & Murphy, E. J. (2009) · Progress in Lipid Research · doi:10.1016/j.plipres.2009.07.002 · Cited by 602
Self-citationα-Linolenic acid: Nutraceutical, pharmacological and toxicological evaluation
Kim, K.-B., Nam, Y. A., Kim, H. S., Hayes, A. W., & Lee, B.-M. (2014) · Food and Chemical Toxicology · doi:10.1016/j.fct.2014.05.009 · Cited by 314
Regulation of brain polyunsaturated fatty acid uptake and turnover
Chen, C. T., Green, J. T., Orr, S. K., & Bazinet, R. P. (2008) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2008.09.003 · Cited by 171
Fatty Acids - Induced Lipotoxicity and Inflammation
Savary, S., Trompier, D., Andreoletti, P., Le Borgne, F., Demarquoy, J., & Lizard, G. (2012) · Current Drug Metabolism · doi:10.2174/138920012803762729 · Cited by 111
Cappa, M., Bizzarri, C., Petroni, A., Carta, G., Cordeddu, L., Valeriani, M., Vollono, C., De Pasquale, L., Blasevich, M., & Banni, S. (2012) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-011-9432-3 · Cited by 49
Bonaventura, E., Alberti, L., Lucchi, S., Cappelletti, L., Fazzone, S., Cattaneo, E., Bellini, M., Izzo, G., Parazzini, C., Bosetti, A., et al. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2022.1072256 · Cited by 27
Metabolites Associated with Early Cognitive Changes Implicated in Alzheimer’s Disease
Darst, B. F., Huo, Z., Jonaitis, E. M., Koscik, R. L., Clark, L. R., Lu, Q., Kremen, W. S., Franz, C. E., Rana, B., Lyons, M. J., et al. (2021) · Journal of Alzheimer’s Disease · doi:10.3233/jad-200176 · Cited by 16
“One of the three fatty acids was erucate (22 : 1n9), an omega-9 fatty acid that readily crosses the blood-brain barrier [53] and has been shown to enhance memory performance in mice [54].”
Is subclinical adrenal failure in adrenoleukodystrophy/adrenomyeloneuropathy reversible
Cappa (2011) · PubMed · doi:10.3275/7570 · Cited by 14
Metadata
- Authors
- Golovko, M. Y., & Murphy, E. J.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2006-06
- Volume
- 47
- Issue
- 6
- Pages
- 1289-1297
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W2147134431
- Cited by
- 70
- References
- 21
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.